ReviewFrontiers in physiology2023
Advances in the study of miRNAs in chronic kidney disease with cardiovascular complications.
Review in Frontiers in physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Effects of Acetylcholine on Endothelial Function and Nitric Oxide Levels in Patients with Type 2 Diabetes Mellitus: A Randomized Sham-Controlled Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Trial
- Association of miR-133a With Microalbuminuria in Patients With Resistant Arterial Hypertension and Chronic Kidney Disease.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Integrative analysis of circ_DLGAP4, lncRNA KCNQ1OT1, and the miR-9/SOX7 interaction network in chronic kidney disease progression: a case-control study.Functional & integrative genomics · 2026Observational
- Emerging Urinary Biomarkers and Innovative Technologies for the Early Detection and Personalized Management of Chronic Kidney Disease.International journal of molecular sciences · 2026Review
- Review
- miR-29a-3p/Renal failure · 2025Article
- New biomarkers of inflammation associated with haemodialysis.Clinical kidney journal · 2025Article
- What a Modern Physician Should Know About microRNAs in the Diagnosis and Treatment of Diabetic Kidney Disease.International journal of molecular sciences · 2025Review
- Human Breast Milk Exosomes: Affecting Factors, Their Possible Health Outcomes, and Future Directions in Dietetics.Nutrients · 2024Review
- Krüppel-like factor 2 is an endoprotective transcription factor in diabetic kidney disease.American journal of physiology. Cell physiology · 2024Review
- MicroRNAs and vascular damage in chronic kidney disease: advances and clinical implications.Jornal brasileiro de nefrologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is characterised by gradual loss of renal function and cardiovascular disease (CVD) as its principal consequence. CVD is a substantial source of morbidity and death in the CKD population and a growing global concern. Because there are no reliable early biomarkers to follow the progression of CKD and predict the risk of complications, research into such molecules continues. Many studies have demonstrated that miRNAs are potentially important variables in CKD, are very stable in blood, and may be employed as diagnostic and prognostic markers for various disorders. Vascular calcification (VC) is a cell-mediated process that necessitates genetic defects in the combined cardiovascular issues of CKD and may be modulated in part by miRNAs. Numerous miRNAs have been linked to the progression of vascular calcification. Many miRNAs have been discovered as being important in ventricular hypertrophy, including miRNA-30, miRNA-212, and miRNA-133. Endothelium miR-126, miR-92a-3p, and others are important regulators of angiogenesis, endothelium repair, and homeostasis. Several interesting non-invasive miRNA biomarkers in CKD/CVD have been found, with the potential to enhance diagnostic accuracy, predict prognosis, track disease progression, and serve as novel therapy targets. However, large-scale clinical studies are still needed to determine the therapeutic utility of miRNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.